Period | Baseline | Inclusion | Treatment | Follow-up | ||
---|---|---|---|---|---|---|
Measurement | Â | 1 | 2 | 3 | 4 | 5 |
Week | -4 | 0 | 4 | 8 | 12 | 16 |
Patients | Â | Â | Â | Â | Â | Â |
Informed consent | Â | Â | Â | Â | Â | Â |
Inclusion/exclusion criteria | × | × |  |  |  |  |
Medical history | × |  |  |  |  |  |
Medical examination | × |  |  |  |  |  |
Combined disease treatment | × | × | × | × | × | × |
Physical examination | × |  |  |  |  |  |
Outcomes | Â | Â | Â | Â | Â | Â |
Angina diary | × | × | × | × | × | × |
The frequency of angina attack | × | × | × | × | × | × |
The dosage of nitroglycerin | × | × | × | × | × | × |
Angina pectoris grade |  | × | × | × | × | × |
The pain severity of angina(VAS) | × | × | × | × | × | × |
SAQ score |  | × | × | × | × | × |
Six minutes’ walk test |  | × | × |  |  |  |
SAS and SDS |  | × | × | × |  | × |
24 hours dynamic ECG |  | × | × |  |  |  |
Cardiovascular events |  |  | × | × | × | × |
Trial evaluation | Â | Â | Â | Â | Â | Â |
Patient’s compliance |  |  | × |  |  | × |
Reasons of drop-out or withdrawals |  |  | × |  |  | × |
Adverse events |  |  |  |  |  | × |
Safety evaluation |  |  |  |  |  | × |